GLP-1 for Obstructive Sleep Apnea

In obstructive sleep apnea the upper airway keeps collapsing during sleep, so breathing stops briefly and you surface again, over and over, often without remembering any of it. Severity is counted as events per hour: 5 to 14 is mild, 15 to 29 moderate, 30 or more severe. Left untreated it fragments sleep, drags on daytime alertness and thinking, and pushes up the risk of hypertension, an irregular heartbeat, heart attack, stroke and diabetes.

Of the risk factors you can change, body fat matters most. Tissue around the neck, tongue and airway narrows the passage and weakens the muscle tone holding it open, while fat around the middle restricts the chest wall and reduces the lung volume that would otherwise keep the airway tethered. A global analysis put around 936 million adults aged 30 to 69 as having some degree of it, with roughly 425 million in the moderate-to-severe range [4]. Population surveys have tracked its prevalence rising alongside obesity for decades [5].

Positive airway pressure remains first-line for moderate-to-severe disease, and its central weakness is that many people will not wear a mask every night. For years the alternatives (positional therapy, oral appliances, airway surgery) worked around the problem without touching what caused it. That changed in 2024, when tirzepatide became the first drug the FDA approved specifically to treat moderate-to-severe sleep apnea in adults with obesity.

The SCALE Sleep Apnea trial [3] was the first proper test of whether shrinking airway fat could treat the disorder. Adults with obesity and moderate-to-severe disease, none using a machine, were randomized for 32 weeks. Liraglutide 3.0 mg cut events by an average of 12.2 an hour against 6.1 on placebo, a treatment difference of 6.1 events an hour. Weight fell 5.7% against 1.6%. A post-hoc look confirmed that the size of the weight loss tracked the size of the improvement, and that finding made the mechanism credible.

Confirmation came from SURMOUNT-OSA, two phase 3 randomized trials published in 2024 [1]. One enrolled people not using a machine, the other people who were; both ran 52 weeks against placebo at the maximum tolerated tirzepatide dose. Starting severity was high, around 51.5 and 49.5 events an hour. In the first trial events fell by 25.3 an hour against 5.3 on placebo; in the second, by 29.3 against 5.5. In proportional terms that is a reduction of roughly a half and three-fifths from baseline.

The gains ran well past the headline count. Both trials showed improvement in hypoxic burden (how much oxygen deprivation accumulates across a night), in reported sleep disturbance, in inflammatory markers, and in systolic blood pressure [1]. A 2026 secondary analysis characterized those cardiometabolic improvements in more detail, documenting changes in inflammation, blood pressure and metabolic measures that matter for cardiovascular risk in their own right [2]. Some of that follows from treating the apnea, and some is what this drug class does anyway.

Those results produced the December 2024 approval of tirzepatide for moderate-to-severe sleep apnea in adults with obesity. It was the first time any drug had been approved for the condition itself, as opposed to its daytime consequences. Several mechanisms plausibly contribute: less fat around the airway, lower systemic inflammation, better respiratory muscle tone, and reduced overnight fluid shifts. Whether there is also a direct effect on respiratory control, beyond the fat loss, is still open.

The approval covers adults with moderate-to-severe disease (15 or more events an hour) who also have obesity. Overweight with a weight-related condition, which qualifies for the weight-management indication, does not qualify for this one. It is licensed as an adjunct to reduced calories and more activity, and can be used with or without a machine. It is not approved for sleep apnea in someone without obesity, and the diagnosis needs confirming by a sleep study or a validated home test first.

People already using a machine successfully can still be candidates, which is what the second trial was designed to show. For them the goal is added control and lower cardiometabolic risk, not replacing the device. The drug is arguably more compelling for those who have refused or abandoned a machine, since treating the underlying obesity reduces severity whether or not a device is worn. Either way, reassess severity after meaningful weight loss, usually 10 to 15%, to see whether pressure settings need changing.

Mild disease, at 5 to 14 events an hour, sits outside the approved indication, though weight loss in that group frequently resolves the problem outright. At the severe end, with class II or III obesity, bariatric surgery remains an alternative or an addition and produces larger, more durable reductions. Choosing between them turns on other conditions, symptom burden, appetite for an invasive option, and whether surgical expertise is available to you.

The common side effects are nausea, vomiting, diarrhea and constipation, and they cluster during escalation. In the trials they were mostly mild to moderate and did not drive high dropout. The standard schedule takes twenty weeks or more to reach the maximum tolerated dose for this reason, and taking the injection with food helps. Expect them to be temporary, not a reason to stop.

For someone with severe or symptomatic disease who is using a machine successfully, the drug does not replace it. The two do different jobs on different timescales: the device handles oxygenation tonight, and the drug addresses the cause across months. Nobody should stop their machine in anticipation of improvement. Stop only after a repeat sleep study, done once weight has stabilized, shows the apnea is controlled without it.

The class contraindications apply here as everywhere: the drug is not for anyone whose own or family history includes medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pancreatitis, gallbladder trouble and sudden kidney injury are all uncommon, and all real risks. What a plan pays against a sleep apnea indication is not necessarily what it pays for weight management, and authorization rules differ between payers, so check which one your approval is written against. The apnea can return if the weight does, so staying on the drug is part of the treatment.